NHF Addresses Potential Contraception Bans
FOR IMMEDIATE RELEASE Abortion and contraception can both be critical components of an individual’s health care journey. However, it is important to not conflate abortion and birth control as one in the same – both are medical in…
Sanofi and Sobi® Report Progress with BIVV001 at International Congress
Sanofi and Swedish Orphan Biovitrum AB (Sobi®) recently shared positive results from the XTEND-1 pivotal phase 3 study of efanesoctocog alfa (BIVV001). BIVV001 is an investigational recombinant factor VIII therapy (rFVIII) developed for the…
Prophylactic Therapy for Glanzmann Thrombasthenia Moves Towards Clinical Trials
The recent Congress of the International Society on Thrombosis and Haemostasis (ISTH) included some noteworthy findings on the rare blood disorders news front. Hemab Therapeutics, which specializes in developing therapies that target serious…
Sanofi Provides Fitusiran Trial Updates at ISTH
Sanofi recently shared new clinical trial updates for their investigational hemophilia therapy fitusiran. The Phase 3 ATLAS-PPX study is evaluating the efficacy and safety of fitusiran (80 mg) when administered prophylactically (once per month) to…
Markers of autoimmunity in immune thrombocytopenia
Markers of autoimmunity in immune thrombocytopenia Speaker(s): Dr. Marie Hollenhorst NHF's Wednesday Webinars are a free education series open to providers and community members. Register to attend and learn…
50 Years of the JGP Research Fellowship
50 Years of the JGP Research Fellowship Speaker(s): NHF Research Team NHF's Wednesday Webinars are a free education series open to providers and community members. Register to attend and learn about the latest…
An exploration of why men with severe haemophilia might not want gene therapy: The exigency study
An exploration of why men with severe haemophilia might not want gene therapy: The exigency study Speaker(s): Simon Fletcher NHF's Wednesday Webinars are a free education series open to providers and…
Paper Features Q&A Resource on Shared Decision Making and Gene Therapy
As investigational hemophilia gene therapies begin receiving regulatory approvals, community stakeholders have recognized the acute need for people with hemophilia (PWH) and healthcare professionals (HCPs) to be fully engaged in shared decision…
Developing a Point-of-Care Testing for Hemophilia
Dr. Jill Johnsen is scientist and physician at the Washington Center for Bleeding Disorders in Seattle, WA.  She is an Associate Member at the Bloodworks Research Institute and also an Associate Professor of Medicine in the Division of…
New Prophylaxis Approval for REBINYN®
Novo Nordisk recently announced that the U.S. Food and Drug Administration (FDA) has approved a supplemental Biologics License Application (sBLA) for REBINYN®, the company’s recombinant, GlycoPEGylated extended half-life therapy. The approval is…